key: cord-1015098-0zti6rwh authors: Hamilton, A. C.; Donnelly, D. W.; Loughrey, M. B.; Turkington, R. C.; Fox, C.; Fitzpatrick, D.; O'Neill, C. E.; Gavin, A. T.; Coleman, H. G. title: Inequalities in the decline and recovery of pathological cancer diagnoses during the first six months of the COVID-19 pandemic: a population-based study date: 2021-02-24 journal: nan DOI: 10.1101/2021.02.23.21252276 sha: 0d4732ea1f9c4269574d37d731a8f33650f7451b doc_id: 1015098 cord_uid: 0zti6rwh Background: The restructuring of healthcare systems to cope with the demands of the COVID-19 pandemic has led to a reduction in clinical services such as cancer screening and diagnostics. Methods: Data from the four Northern Ireland pathology labs was used to assess trends in pathological cancer diagnoses from 1st March to 12th September 2020 overall and by cancer site, gender and age. These trends were compared to the same timeframe from 2017-2019. Results: Between 1st March and 12th September 2020 there was a 23% reduction in cancer diagnoses compared to the same time period in the preceding three years. Although some recovery occurred in August and September 2020, this revealed inequalities across certain patient groups. Pathological diagnoses of lung, prostate and gynaecological malignancies remained well below pre-pandemic levels. Males and younger/middle-aged adults, particularly the 50-59 year old patient group, also lagged behind other population demographic groups in terms of returning to expected numbers of pathological cancer diagnoses. Conclusions: There is a critical need to protect cancer diagnostic services in the ongoing pandemic to facilitate timely investigation of potential cancer cases. Targeted public health campaigns may be needed to reduce emerging inequalities in cancer diagnoses as the COVID-19 pandemic continues. The COVID-19 pandemic is an unprecedented global challenge that has had profound effects on 42 healthcare systems. The rapid transformation of clinical services across the world, such as the opening 43 of Nightingale Hospitals in the UK, has required a significant effort from healthcare personnel and 44 governments. The redeployment of staff and resources directed towards managing COVID-19 has had 45 a significant impact on provision of routine medical care, with many such services being reduced or 46 cancelled. 47 observed breast and colorectal cancer diagnoses in the population as a whole, but particularly in the 74 screening age groups, with recovery to expected levels by late June 2020. (8) In contrast to this, a Korean 75 study of lung cancer cases in three hospitals found that the number of lung cancer diagnoses from 76 February to June 2020 did not differ significantly from the previous 3 years. (9) Finally, a Danish study 77 investigating all-cause mortality rates (including cancer mortality) from 1 st January through to 5 th July 78 2020 found that there was no excess mortality as a result of COVID-19 or the resulting lockdown in 79 Denmark. (10) This is in contrast to several other European countries, including the UK, which had shown 80 excess all-cause mortality by May 2020. (11) 81 Given the findings of modelling studies (5, 6) and limited data published to date, there remains an urgent 82 need to quantify the impact of COVID-19 on cancer diagnoses using real-world data. The aim of this 83 study was to evaluate the impact of COVID-19 on pathological diagnoses of cancer using data collated 84 by the population-based Northern Ireland Cancer Registry (NICR). A secondary aim was to evaluate 85 potential inequalities in the pathological cancer diagnosis trends observed by subgroups of cancer 86 type, patient age, sex and for screen-detected cancer. 87 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The distribution of cancer diagnoses by site is shown in Figure 2 . The number of diagnoses across all 133 cancer sites was reduced during the overall period from 1 st March to 12 th September 2020 compared 134 to the same time period in the preceding three years. However, in August and September, there were 135 signs of recovery in the number of diagnoses across several cancer sites, with colorectal cancer, breast 136 cancer and haematological malignancies showing a 12%, 6% and 30% increase respectively compared 137 to previous years. Of concern though, lung, prostate and gynaecological cancer diagnoses remained 138 considerably lower than expected during this most recent five week time frame, at 21%, 10% and 18% 139 respectively below expected numbers of pathological diagnoses. 140 Analysis by screen-detected colorectal and breast cancers 141 Trends for colorectal cancer and breast cancer for the general population and for the screening age 142 population (60-74 years for colorectal cancer and 50-70 years for breast cancer) are shown in Figure 143 3. The number of colorectal cancer diagnoses was reduced for all ages and for the screening age 144 population during the overall six month period studied compared to previous years. From 9 th August 145 to 12 th September 2020 the total number of colorectal cancer diagnoses increased by 12%, compared 146 to previous years, indicating some recovery for the population as a whole. However, in the screening 147 age population, the number of diagnoses remained significantly reduced, by 18% lower than previous 148 years. The number of breast cancer diagnoses was reduced for both the general and screening age 149 population during the overall six month period studied in 2020 compared to previous years. In the 150 more recent five week period studied however, recovery was evident in both groups, with an increase 151 of 6% overall and 14% in the screening age group, in the number of breast cancer cases compared to 152 previous years. 153 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 24, 2021. ; https://doi.org/10.1101/2021.02.23.21252276 doi: medRxiv preprint Both sexes were relatively equally affected overall, with a 22% and 23% reduction in cancer diagnoses 155 in males and females during the overall pandemic time period (Figure 4 ). However, when studying the 156 most recent five week time period from 9 th August to 12 th September 2020, males lagged somewhat 157 behind females, with observed 8% and 2% lower numbers of pathological cancer diagnoses, 158 respectively. 159 The number of cancer diagnoses across age categories recorded from 1 st March to 12 th September 160 2020 is shown in Figure 5A is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint contributing. Some cases are likely due to failure by the patient to report concerning symptoms for 177 investigation. Failure to engage with the healthcare system may reflect patient fear regarding 178 contracting COVID-19, or an effort on their part to "protect the NHS", given national guidance to this 179 effect, or limited ability to use telephone consultations. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint February to June 2020 did not differ significantly from the previous three years. (9) However, this study 208 did also report that the number of stage III-IV non-small-cell lung cancer cases was significantly higher 209 in 2020 compared to previous years (74.7% compared to 57.9-66.7% in 2017-19). (9) Unfortunately we 210 do not have staging information for the cancer data presented in this article as yet, but a shift in 211 distribution to later stage at presentation is likely to be seen for cancer patients in the coming months 212 and years. There is limited generalisability between the UK and South Korea in terms of experience 213 during the COVID-19 pandemic. Nevertheless, it is concerning and predicted that these 'missed' cancer 214 patients are likely to present with a more advanced cancer, and therefore have poorer outcomes, at 215 some point in the future. 216 The increased number of breast cancer diagnoses from 9 th August to 12 th September 2020 for the 217 whole population, and in those of screening age, suggests the successful resumption of cancer 218 screening is contributing to the observed recovery in numbers of cancer diagnoses. In contrast to 219 investigation of other cancers, such as lung cancer, diagnosis of breast cancer does not require an 220 aerosol-generating procedure and personal protective equipment, therefore capacity for breast 221 cancer investigations is likely to be nearer normal pre-pandemic levels. These results are in keeping 222 with trends in the Netherlands, which showed a steep decline in breast cancer cases during the initial 223 stages of the pandemic, with the screening age population more affected than women of non-224 screening age. (8) However, in the Netherlands the non-screening age group recovered more quickly to 225 expected levels, whereas our results suggest a more rapid recovery in the screening age group. 226 In contrast to breast cancer screening which resumed in mid-July 2020, colorectal cancer screening 227 invitations did not resume in Northern Ireland until mid-August 2020. Furthermore, the colorectal 228 cancer screening pathway involves the secondary step of colonoscopy prior to cancer diagnosis and 229 expected levels. In addition, some cancer sites such as melanoma, head & neck and upper GI cancers 270 have seen the numbers of diagnoses reduce by 37%, 27% and 23% respectively, despite showing 271 recovery in the previous 5 week period studied. This illustrates the unpredictable nature of cancer 272 diagnostics during an international pandemic, the need for ongoing data collection, and the realisation 273 that the impact of COVID-19 won't be fully understood until several more months, if not years, have 274 passed. Nevertheless, the need for timely understanding of the impact of the COVID-19 pandemic on 275 cancer diagnoses has required such approaches to be undertaken. 276 In summary, this population-based study has quantified the impact of the COVID-19 pandemic on 277 reducing by 23% the number of cancer diagnoses during the first six months of the pandemic in a UK 278 region. There are emerging inequalities by cancer site and population subgroups in cancer diagnoses 279 which require further investigation to optimise recovery pathways. Additional variables, such as 280 socioeconomic status, may also be contributing to the observed inequalities, and could be included in 281 future research. As the COVID-19 pandemic continues, measures to mitigate the impact on cancer 282 diagnoses must be taken in the areas of public education and awareness campaigns, rapid access to 283 healthcare professionals, referral pathways and diagnostic capacity. It is expected that the observed 284 reduction in cancer diagnoses, and particularly screen-detected cancers, will translate into diagnosis 285 at more advanced stages of disease for those patients in whom investigations were delayed, and 286 therefore poorer survival outcomes. Longer-term data are needed, including information on cancer 287 site, stage, treatment and outcomes, to fully assess the impact of COVID-19 on cancer care, and to 288 assist with ongoing service recovery planning. 289 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 24, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 24, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 24, 2021. ; https://doi.org/10.1101/2021.02.23.21252276 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 24, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted February 24, 2021. ; https://doi.org/10.1101/2021.02.23.21252276 doi: medRxiv preprint Validation of the 363 completeness and accuracy of the Northern Ireland Cancer Registry Northern Ireland Cancer Registry. The impact of the Covid-19 on cancer diagnosis Strategies for Digital Care of Vulnerable Patients in a 369 COVID-19 World-Keeping in Touch